HERIZON-GEA-01: Zanidatamab + chemo ± tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma
| Autor: | Josep Tabernero, Lin Shen, Elena Elimova, Geoffrey Ku, Tianshu Liu, Kohei Shitara, Xiao Lin, Lisa Boyken, Huiyan Li, Jonathan Grim, Jaffer Ajani |
|---|---|
| Přispěvatelé: | Institut Català de la Salut, [Tabernero J] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. UVic-UCC, IOB-Quiron, Barcelona, Spain. [Shen L] Department of Gastrointestinal Oncology, Key laboratory of Carcinogenesis & Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Beijing, China. [Elimova E] Princess Margaret Cancer Centre, Toronto, Ontario, Canada. [Ku G] Memorial Sloan Kettering Cancer Center, New York, USA. [Liu T] National Cancer Center Hospital, Kashiwa, Chiba, Japan. [Shitara K] Zhongshan Hospital, Shanghai, China, Vall d'Hebron Barcelona Hospital Campus |
| Rok vydání: | 2022 |
| Předmět: |
Cancer Research
Esophageal Neoplasms Receptor ErbB-2 Programmed Cell Death 1 Receptor neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias gastrointestinales::neoplasias del esófago [ENFERMEDADES] Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores] Antineoplastic Agents Adenocarcinoma Other subheadings::Other subheadings::/drug therapy [Other subheadings] Antibodies Monoclonal Humanized Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Esophageal Neoplasms [DISEASES] Esòfag - Càncer - Tractament Stomach Neoplasms Antineoplastic Combined Chemotherapy Protocols Humans aminoácidos péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos monoclonales [COMPUESTOS QUÍMICOS Y DROGAS] Anticossos monoclonals - Ús terapèutic Neoplasms::Neoplasms by Histologic Type::Neoplasms Glandular and Epithelial::Carcinoma::Adenocarcinoma [DISEASES] neoplasias::neoplasias por tipo histológico::neoplasias glandulares y epiteliales::carcinoma::adenocarcinoma [ENFERMEDADES] Antibodies Monoclonal General Medicine Trastuzumab Adenocarcinoma - Tractament Oncology Esophagogastric Junction Amino Acids Peptides and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies Monoclonal [CHEMICALS AND DRUGS] |
| Zdroj: | Scientia |
| ISSN: | 1744-8301 |
| Popis: | HER2-positive gastroesophageal adenocarcinomas (GEAs) are common cancers with high mortality and the treatment options for advanced/metastatic disease are limited. Zanidatamab and tislelizumab are novel monoclonal antibodies targeting HER2 and PD-1, respectively, and have shown encouraging antitumor activity in early phase studies in multiple cancers, including GEA. Preliminary data suggest that dual targeting of the HER2 and PD-1 pathways could further improve upon the results achieved with targeting either pathway alone. Here, we describe the design of HERIZON-GEA-01, a global, randomized, open-label, active-comparator, Phase III study to evaluate and compare the efficacy and safety of zanidatamab plus chemotherapy with or without tislelizumab to the standard of care (trastuzumab plus chemotherapy) as first-line treatment for patients with advanced/metastatic HER2-positive GEAs.HERIZON-GEA-01: A phase III study of zanidatamab + chemotherapy ± tislelizumab for first-line treatment of advanced or metastatic #HER2-positive gastroesophageal adenocarcinoma (GEA). Clinicaltrials.gov: NCT05152147. #gastriccancer #stomachcancer @ZymeworksInc @BeiGeneGlobal |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|